<DOC>
	<DOCNO>NCT00275951</DOCNO>
	<brief_summary>The investigator initial evidence combination cetuximab cisplatin-HDFL may improve efficacy cisplatin-HDFL combination chemotherapy .</brief_summary>
	<brief_title>Cetuximab Plus P-HDFL First-line Treatment Advanced Gastric Cancer</brief_title>
	<detailed_description>The clinical efficacy ( confirm objective response rate , progression-free survival , overall survival ) , treatment-related toxicity novel regimen examine first-line treatment patient nonresectable recurrent/metastatic gastric cancer .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Age 18 75 year 2 . Histologically proven adenocarcinoma 3 . At least one `` measurable '' lesion ( RECIST ) 4 . No prior chemotherapy gastric cancer 5. WHO performance status â‰¦ 2 6 . Adequate baseline organ function 7 . Fasting serum triglyceride level &gt; 70 mg/dL 8 . Written inform consent 9 . At least one month gastrectomy 10 . Availability tumor sample immunohistochemical pharmacogenomic test EGFR 1 . Concomitant anticancer biological agent , chemotherapy , radiotherapy 2 . CNS metastasis 3 . Pregnancy , breastfeed woman woman childbearing potential 4 . Life expectancy le 3 month 5 . Serious concomitant illness 6 . Concurrent prior second malignancy 7 . Known hypersensitivity reaction component study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Combination</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Gastric cancer</keyword>
</DOC>